{"filings":[{"id":92356,"accession_number":"0001214659-26-005746","cik":1347123,"company_name":"EBR Systems, Inc.","ticker":"EBRCZ","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"EBR Systems shareholders elect directors, approve equity increase and option grants at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected John McCutcheon and Bronwyn Evans as Class II directors to hold office until 2029; ~219.3M votes for each.","Approved addition of 18,010,366 shares under 2021 Equity Incentive Plan (166.6M for, 12.1M against).","Approved CEO John McCutcheon option grant valued at $716,154 (175.7M for).","Approved option grants to Allan Will ($160k), Karen Drexler ($130k), Trevor Moody ($130k), David Steinhaus ($130k), and nominees of Evans and Nave ($130k each)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2050036017.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92355,"accession_number":"0001214659-26-004488","cik":1347123,"company_name":"EBR Systems, Inc.","ticker":"EBRCZ","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"EBR Systems Q1 preliminary revenue $2.25-$2.36M; commercial cases double QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited Q1 2026 revenue $2.25M-$2.36M; financial close not yet complete.","41 WiSE implants in Q1 2026, more than double Q4 2025; cumulative 71 commercial implants.","Added 16 purchase agreements (total 37) and 22 trained physicians (total 55) in Q1.","1-for-10 reverse stock split effective April 1; CDI conversion ratio changed to 10:1.","Management cites strong commercial momentum, expanding site readiness and physician training."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":2362000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2050036017.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103156,"accession_number":"0001214659-26-003845","cik":1347123,"company_name":"EBR Systems, Inc.","ticker":"EBRCZ","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"EBR Systems announces 1-for-10 reverse stock split effective April 1, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-10 reverse split ratio on March 17, 2026; stockholders authorized ratio range of 1:5 to 1:20.","Reverse split effective April 1, 2026 at 4:00 a.m. ET; every 10 pre-split shares become 1 share.","Fractional shares rounded up to nearest whole share; CDI conversion ratio changes from 1:1 to 10:1.","No change in authorized shares or par value; ASX last day for pre-split trading is March 30, 2026 (Australian time)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2050036017.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103155,"accession_number":"0001214659-26-003274","cik":1347123,"company_name":"EBR Systems, Inc.","ticker":"EBRCZ","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"EBR Systems shareholders approve reverse stock split (1:5-1:20) and 55.9M CDI issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split proposal passed with 233.2M for, 970K against; board may set ratio 1:5 to 1:20 or abandon.","Ratification of 55.9M CDIs at A$1.00 per CDI approved (215.8M for, 1.0M against).","Adjournment proposal also approved (233.0M for) to solicit additional proxies if needed.","Special meeting held March 11, 2026; all three proposals carried."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2050036017.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103154,"accession_number":"0001214659-26-000377","cik":1347123,"company_name":"EBR Systems, Inc.","ticker":"EBRCZ","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"EBR Systems reports Q4 2025 preliminary rev ~$900K; WiSE implants double QoQ, clinical studies advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 revenue $870K-$935K; FY2025 revenue $1,552K-$1,617K (unaudited, subject to audit adjustments).","Commercial WiSE implants doubled QoQ to 18 in Q4, reaching 30 total for the year; 9 new purchase agreements signed.","WiSE-UP post-approval study enrolled 4 patients; TLC-AU feasibility study enrolled first patient in Australia.","11 additional physicians trained in Q4, bringing total trained to 33 across 21 centers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":1617000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2050036017.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152972,"accession_number":"0001214659-25-008505","cik":1347123,"company_name":"EBR Systems, Inc.","ticker":"EBRCZ","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"EBR Systems raises ~$36M via 55.9M CDI placement at A$1.00 per CDI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 55.9M CDIs at A$1.00 (~US$0.6434), raising ~US$36M gross before ~$2.25M fees.","Placement fully underwritten by J.P. Morgan Securities Australia and Morgans Corporate; settled May 26, 2025.","Joint lead managers: J.P. Morgan, Morgans, Wilsons Corporate Finance, and E&P Capital.","Concurrent non-underwritten SPP announced to raise ~A$6M (approx. US$3.86M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2050036017.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152971,"accession_number":"0001214659-25-008249","cik":1347123,"company_name":"EBR Systems, Inc.","ticker":"EBRCZ","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"EBR Systems shareholders approve all 11 proposals at 2025 annual meeting, including officer liability amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected Class I directors Allan Will and Trevor Moody to hold office until 2028 annual meeting.","Ratified issuance of 45,568,852 CDIs at A$0.82 per CDI under ASX Listing Rule 7.4.","Approved amendment to 2021 Equity Incentive Plan to eliminate Section 9(c) and issuance of securities.","Approved option grants totaling US$1,225,000 to CEO John McCutcheon and smaller grants to other officers.","Filed Certificate of Amendment to limit officer liability per Delaware law on May 22, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2050036017.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152970,"accession_number":"0001214659-25-005919","cik":1347123,"company_name":"EBR Systems, Inc.","ticker":"EBRCZ","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CMS proposes NTAP reimbursement for EBR's WiSE CRT at max 65% rate","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS proposed NTAP for WiSE CRT System for FY 2026 at maximum add-on payment of 65% of device cost.","NTAP is in addition to standard MS-DRG payment, intended to fully cover device cost.","NTAP effective from 1 Oct 2025 for three years, subject to final CMS rule expected August 2025.","EBR plans to apply for Transitional Pass-through reimbursement for outpatients shortly.","FDA approval of WiSE CRT also announced; both milestones advance US commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2050036017.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152969,"accession_number":"0001214659-25-005814","cik":1347123,"company_name":"EBR Systems, Inc.","ticker":"EBRCZ","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves EBR Systems' WiSE CRT System for commercial distribution in US","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved WiSE CRT System for left ventricular endocardial pacing; target initial US addressable market ~$3.6B.","Indicated for previously untreatable (failed CS lead) and high-risk upgrade patients aged ≥22.","Limited market release in late 2025; full commercial launch expected early 2026.","Post-approval study of 320 patients over 5 years required; NTAP/TPT reimbursement effective Oct 1, 2025.","Contraindications include triple anticoagulant therapy and allergy to procedural agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2050036017.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171757,"accession_number":"0001214659-25-004571","cik":1347123,"company_name":"EBR Systems, Inc.","ticker":"EBRCZ","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"EBR Systems amends bylaws to reduce stockholder quorum from majority to one-third","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amendment on March 18, 2025, effective immediately.","Quorum reduced from majority to one-third of outstanding shares for stockholder meetings.","Amended Bylaws filed as Exhibit 3.1 to the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2050036017.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}